- Reveals core business strategies at JP Morgan Healthcare Conference press briefing
- Further strengthening the 에볼루션 바카라 business…Seven follow-up pipeline products unveiled
- IND candidate approved…Plans to add at least one new candidate each year
- President Kim Kyung-ah: “Advancing toward a ‘Korean Big Pharma model’…Leading the future of K-Bio”
[by Ji, Yong Jun] 에볼루션 바카라 Epis Holdings announced on January 14 (local time) that it held a press conference at the JP Morgan Healthcare Conference in San Francisco, USA, during which it presented its core business strategies alongside its research and development (R&D) roadmap.
Kim Kyung-ah, president and CEO of Samsung Epis Holdings and its subsidiaries (Samsung Bioepis and Epis NexLab), stated at the press conference that, "Building on the strong performance and proven success of our core biosimilar business, we plan to expand our business into new drug development."
에볼루션 바카라 Bioepis' biosimilar portfolio is currently marketed in more than 40 countries worldwide. Kim explained that, supported by sustained growth in global sales, the company has established a stable and recurring profit structure.
"We plan to proactively expand our biosimilar portfolio to a total of 20 products by 2030. At present, we are developing biosimilars targeting seven blockbuster drugs: Keytruda, Dupixent, Tremfya, Taltz, Enhertu, Entyvio, and Ocrevus," Kim remarked.
Regarding the expansion of novel drug development, Kim stated, "We have recently obtained Investigational New Drug (IND) approval for our antibody-drug conjugate (ADC) candidate, 'SBE303 (development code).’ Beginning next year, we plan to advance at least one new drug candidate into the clinical trial stage on an annual basis."
에볼루션 바카라 Epis Holdings emphasized that its approach to new drug development prioritizes rigorous scientific validation and a stepwise strategy for building market credibility, rather than focusing on short-term outcomes or rapid, superficial expansion of its pipeline.
On the other hand, Samsung Epis Holdings is securing new growth drivers in multiple business areas, including the advancement of next-generation therapeutic technology platform R&D through its newly established subsidiary, Epis NexLab. “Building on the achievements of our biosimilar business, we will accelerate new drug development and evolve into a ‘Korean Big Pharma model’ recognized on the global stage. Through these efforts, we aim to maximize shareholder value and play a leading role in shaping the future of Korea’s biopharmaceutical industry,” Kim said.